ProPharma Group, a provider of regulatory, clinical and quality services for the life sciences industry and a portfolio company of Odyssey Investment Partners, has appointed Karl Deonanan to chief financial officer.
Deonanan joins ProPharma with a track record of delivering business growth and profitable financial results. He will be responsible for leading ProPharma’s finance functional areas, including financial planning and analysis, accounting and treasury operations. Most recently, he served as the chief financial officer at X-Chem. Prior to joining X-Chem, Deonanan held several executive finance leadership roles with life sciences organizations including Synteract and IQVIA, where he was the CFO of the company’s research and development solutions segment amongst several other roles, including vice president of investor relations.
“With his extensive experience in financial management, budgeting, and strategic planning, Karl brings a wealth of expertise to our organization,” says Michael Stomberg, CEO of ProPharma. “His proven track record in the pharma services and drug development industry will undoubtedly contribute to our continued growth and success.”